Le Lézard
Classified in: Health, Covid-19 virus
Subject: FEA

Webinar Helps Employers and Health Plans Navigate Increased Elective Surgery Demands Post COVID-19


HOUSTON, Oct. 29, 2020 /PRNewswire/ -- 2nd.MD, the leading provider of virtual specialty care, is offering a complimentary webinar on Friday, November 6 at 1pm ET. The New Normal | Managing Cancer Care Through COVID-19 and Beyond, will guide employers and health plans on how to best assist their members with accessing quality cancer care while elective procedure restrictions continue to lift.

Attendees will gain insight into understanding key concerns, trends, and solutions that can effectively manage a post-COVID-19 surge in oncology care. The hour-long webinar will feature Marsha Hyslop, Chief Clinical Officer, 2nd.MD and Dr. Charles Balch, Professor and Past Head of Surgery, University of Texas MD Anderson Cancer Center.

"We are excited to provide employers and health plans with our timely white paper, webinar, and live Q&A with a world-renowned oncologist who will help them understand how 2nd.MD's virtual consultation service, compassionate oncology nurses, and elite-level oncologists can be trusted resources for education, guidance and advocacy when it comes to accessing cancer care," said Marsha Hyslop, Chief Clinical Officer at 2nd.MD.

This webinar is in response to hospitals shifting focus to emergency and essential services as COVID-19 cases rose this spring, resulting in the unprecedented postponement of elective surgeries.

"As new insights on the rapidly changing landscape of COVID-19 emerge, it's important to 2nd.MD that the healthcare industry knows we are here for them and aim to provide them with relevant, valuable guidance on oncology care and increased elective surgery demands as this situation evolves," said Jason Melton, CEO of 2nd.MD.

Attendees will receive a complimentary white paper entitled Navigating Increased Elective Surgery Demands During a Global Pandemic.

To register for the Managing Cancer Care Through COVID-19 and Beyond webinar, click here.

About 2nd.MD

2nd.MD is the leader in virtual specialty care. A preferred partner to over 250 employers and the country's top health plans, 2nd.MD connects more than 7 million people to over 800 nationally recognized, board-certified medical specialists covering all adult and pediatric specialty conditions. Providing a world-class member experience and consistently achieving a +90 Net Promoter Score, 2nd.MD combines advanced technology, data, and clinical expertise to save and improve lives every day. For more information, please visit 2nd.MD or follow @2nd.MD on LinkedIn.

SOURCE 2nd.MD


These press releases may also interest you

at 02:28
Allied Market Research published a report, titled, "Pet Insurance Market by Policy Coverage (Accident Only, Accident and Illness, and Others), Animal Type (Dogs, Cats, and Others), and Sales Channel (Agency, Broker, and Others): Global...

at 02:00
Bradda Head Lithium Ltd (AIM:BHL), the North America-focused lithium development group, is pleased to announce that it has come to a settlement regarding the fraudulent payment first notified on 29 March 2022 and subsequently disclosed in the audited...

at 00:25
Zai Lab Limited and Innoviva Specialty Therapeutics today announced that China's National Medical Products Administration (NMPA) has approved Zai Lab's New Drug Application (NDA) for XACDURO® (sulbactam-durlobactam) for the treatment of...

19 mai 2024
ICIS, a global source of commodity intelligence, has announced the 16th Asian Base Oils and Lubricants Conference will take place in Singapore, 27-28 June 2024. The event offers a platform for senior executives to connect with peers, potential...

19 mai 2024
The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or...

19 mai 2024
Amgen and AstraZeneca today announced the results of the Phase 2a COURSE trial evaluating Tezspire® (tezepelumab-ekko) in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of baseline blood...



News published on and distributed by: